All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Gemphire Therapeutics Inc., of Livonia, Mich., reported preclinical data testing gemcabene in the STAM mouse model of non-alcoholic steatohepatitis (NASH). The highest dose of gemcabene produced a significant histological reduction in the nonalcoholic fatty liver disease activity score.